All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Cassava Sciences in-licenses Yale University patent for using simufilam (targeting FLNA) to treat seizures in rare neurodevelopmental disorders
Small molecule, seizure disorder, tuberous sclerosis complex - Read more

Zevra Therapeutics sells Rare Pediatric Disease Priority Review Voucher for $150M
Pediatric rare disease priority review voucher - Read more

PRESENTED BY TLDR BIOTECH
What would you do with nearly 6,000 meticulously tagged biotech & pharma data points?

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

We’re leveraging this resource to build tailored reports and curated insights for select clients—and we’re opening up limited access to interested parties.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Sorriso Pharmaceuticals touts positive Ph1b data for SOR102 (targeting TNFα and IL-23p19) in ulcerative colitis
Bispecific antibody, ulcerative colitis - Read more

Belite Bio touts positive Ph3 data for Tinlarebant (non-ATP cell cycle inhibitor) in adolescent Stargardt disease
Small molecule, Stargardt disease - Read more

YolTech Therapeutics' YOLT-101 (targeting PCSK9) reduces LDL-C levels in familial hypercholesterolemia Ph1 trial
Gene-editing, familial hypercholesterolemia, base-editing, in-vivo - Read more [Press release in Chinese]

Cogent Biosciences showcases positive expanded Ph2 data for bezuclastinib (tyrosine kinase inhibitor) in systemic mastocytosis
Small molecule, systemic mastocytosis - Read more

LEO Pharma's touts positive Ph3 results, meeting primary endpoint, for Anzupgo (topical JAK inhibitor) in chronic hand eczema.
Small molecule, eczema, topical - Read more

Cognition Therapeutics' oral zervimesine (sigma-2 receptor modulator) shows promise in Ph2 trial to treat geographic atrophy secondary to dry age-related macular degeneration
Small molecule, geographic atrophy, geographic atrophy secondary to dry age-related macular degeneration - Read more

Henlius Biotech's Hanquyou (targeting HER2) shows comparable 3-year efficacy to reference trastuzumab for HER2-positive metastatic breast cancer in Ph3 trial
Monoclonal antibody, breast cancer, biosimilar - Read more

Imunon's IMNN-101 DNA plasmid vaccine (targeting SARS-CoV-2 Omicron spike protein) shows safety and antibody response in Ph1 trial for coronavirus disease
DNA, vaccine, COVID-19 - Read more

Kairos Pharma touts preclinical data for KROS101 (GITR agonist) in melanoma and glioblastoma, and KROS401 (macrophage peptide inhibitor) for glioma
Small molecule, cancer, melanoma, glioblastoma - Read more

THE GOOD
Earnings & Finances

Madrigal's MASH drug Rezdiffra (targeting THR-β) shows blockbuster potential with $180 million in first nine months of sales
Small molecule, Metabolic dysfunction-associated steatohepatitis (MASH), Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH) - Read more

BeiGene's Brukinsa (BTK inhibitor) surpasses AstraZeneca's Calquence (BTK inhibitor) in quarterly sales, doubling to $828 million, as CEO cites major opportunity
Small molecule, leukemia, cancer - Read more

THE GOOD
Fundraises

Renovaro $15M equity commitment, AI-powered cancer diagnostics and personalized immunotherapy for healthcare
Diagnostics, cancer detection/screening, AI - Read more

BiomX $12M registered direct offering and private placement, bacteriophage therapies to treat CF with chronic pulmonary infections caused by P. aeruginosa 
Bacteriophage, Pseudomonas aeruginosa infection, cystic fibrosis (CF), pulmonary infection - Read more

Avitia $5M Seed, AI-focused diagnostics company developed NGS-based cancer mutation and applicable treatment screening tech
AI, next generation sequencing (NGS), cancer detection/screening, liquid biopsy - Read more

Loyal $22M Series B-2, developing drugs to extend dogs' lifespans by targeting aging mechanisms
Animal health - Read more

THE GOOD
Mergers & Acquisition

Renovaro and BioSymetrics merge to boost AI-driven biomarker discovery for cancer diagnostics and precision medicine
Biomarker, precision medicine, drug discovery, AI - Read more

N2OFF acquires MitoCareX, an Israeli biotech company developing cancer therapies targeting mitochondrial proteins.
Small molecule, cancer, drug discovery, protein modelling - Read more

Teleflex plans to split into two companies, while acquiring Biotronik's cardiovascular portfolio for $791M, including stents and balloons
Medical device - Read more

THE GOOD
Partnerships

Medigene, EpimAb Biotherapeutics co-developing TCR-guided T Cell Engagers for solid tumors through combined platform technologies
Cell therapy, TCR-guided T cell engager, allogeneic cell therapy, immune-related disorder, solid tumors, cancer, drug development - Read more

myTomorrows, Patient Knows Best partner to match UK patients with clinical trials using personal health records
Clinical trial enrolment, clinical trial access - Read more

THE GOOD
Politics & Policy

Eli Lilly, Bristol Myers Squibb, Sanofi and Roche defy Trump administration’s DEI stance, affirming commitment to diverse clinical trials
DEI, clinical trial diversity - Read more

THE GOOD
Product Launches

Owkin launches ATLANTIS AI to extract knowledge from diverse medical data, fueling drug discovery and diagnostics via Owkin K
AI, patient data - Read more

THE GOOD
Public Health

US to spend $1 billion fighting bird flu outbreak that has killed 166 million chickens and infected dairy herds and humans
Bird flu (H5N1/Avian flu) - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development

Moderna's $590M contract to develop mRNA bird flu vaccines under review as US government scrutinizes spending on mRNA tech
Vaccine contract, mRNA, Bird flu (H5N1/Avian flu), US Department of Health & Human Services (HHS) - Read more

THE BAD
Clinical Trials

Kallyope's Phase II trial showed limited weight-loss benefits from its nutrient receptor agonists KL-757 and K-833 in obese adults
Small molecule, obesity - Read more

THE BAD
Layoffs

Eisai laying off 121 US employees as part of ongoing US restructuring initiative
Big pharma layoffs - Read more

Mission Therapeutics shuts UK preclinical labs to focus on clinical heart failure and Parkinson's programs MTX325 and MTX652
Small molecule, heart failure, Parkinson's disease, Alzheimer's disease - Read more [Paywall]

THE BAD
Partnerships

Vertex Pharmaceuticals, Verve Therapeutics end gene editing collaboration for liver disease amid shifting priorities
Gene-editing, liver disease, research & development - Read more

Silence Therapeutics, Hansoh Pharma partnership ends as Hansoh withdraws from $1.3B collaboration on mRNAi platform targeting three preclinical candidates
mRNAi, nucleic Acid, cardiovascular disease, metabolic disease - Read more

THE BAD
Strategic Plans

Vir Biotechnology pauses hepatitis B combo treatment development until finding partner, awaiting 24-week data on potential functional cure
Small molecule, hepatitis B infection - Read more

Regeneron abandons accelerated approval ambitions for odronextamab (targeting CD20, CD30) in B-cell lymphoma due to competition, focusing only on follicular lymphoma
Bispecific antibody, lymphoma, cancer, accelerated approval - Read more

Xencor pauses vudalimab (targeting PD-1, CTLA4) development, shifting focus from oncology to autoimmune diseases
Bispecific antibody, prostate cancer, lung cancer, autoimmune disease - Read more

THE UGLY
Adverse Events

CDC investigating five cardiac/neurologic hospitalizations in seniors after receiving Valneva's chikungunya vaccine Ixchiq
Vaccine, Chikungunya virus, adverse event, vaccine injury - Read more

THE UGLY
Public Health

Federal vaccine injury compensation advisory panel remains postponed since January with no scheduled resumption.
Vaccine, vaccine panel, US Department of Health & Human Services (HHS) - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here